Welcome

Vectron Biosolutions AS is your expert on developing cost-effective production processes for industrial proteins in E. coli and other bacteria.

We currently offer free feasibility studies where we test a limited set of our expression vector platform to see if it has the potential to be used as a production technology for our clients proteins. This feasibility study takes 2-3 weeks and will give an answer to whether our technology is suited as the production platform for specific proteins.

A positive outcome of the feasibilty study can then initiate a full production process development where the genetics and fermentation conditions are optimized. The resulting bacterial strain and associated protocols for HCDC are then transferred to our clients under a licensing agreement or transferred to one of Vectron's CMO partners for production.

News

February 2016
Upcoming events: CEO Forum in Zurich (March), BIO-Europe Spring in Stockholm (April), and Bionetwork East in Orlando (May), BIO Congress in San Francisco (June).

February 2016
Due to illness Svein Valla has unfortunately left the Board of Vectron. New members are Carl-Åke Carlson and Trygve Brautaset.

February 2016
Vectron is again featured on the front page of Adresseavisen.

September 2015
Vectron is again featured in Adresseavisen, including the frontpage. Read the article here (subscription required). 

September 2015
Vectron is featured in Adresseavisen. Read the articles here and here.

September 2015
Vectron is featured in Dagens Næringsliv. Read the article here.

September 2015
Boehringer Ingelheim licenses Vectron Biosolutions' expression technology platform. Read the press release.

more